Top Markets
#1 Helium Helium +61.05%
#2 Seeker Seeker +36.78%
#3 Pons Pons +29.11%
#4 Zylo Ecosystem Zylo Ecosystem +27.38%
#5 TENDIES TENDIES +26.94%
#6 Bounce Bounce +21.20%
#7 UnifAI Network UnifAI Network +20.79%
#8 DAPPOS DAPPOS +14.63%
#9 Songbird Songbird +14.46%
#10 pipedog pipedog +14.20%
Coin of the day
Helium Helium
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Clasificación en acciones #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Precio por acción
$9.50
Última sincronización: 2025-01-08
Capitalización bursátil
$819.52M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Poseida Therapeutics, Inc. (PSTX)

Categoría

Healthcare
Ratio P/B de Poseida Therapeutics, Inc. (PSTX)
Ratio P/B al August 2026 TTM: 8.26
Según los informes financieros más recientes y el precio de las acciones de Poseida Therapeutics, Inc., el ratio P/B actual (TTM) es 8.26. Al final de 2022, el ratio P/B era 2.03.
Historial del ratio P/B de Poseida Therapeutics, Inc. desde 2016 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) 8.26 182.94%
2023 2.92 43.83%
2022 2.03 -25.05%
2021 2.71 10.84%
2020 2.45 -159.95%
2019 -4.08 -43.25%
2018 -7.19 -60.46%
2017 -18.18 -132.79%
2016 55.46 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -23.24%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -24.46%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -69.67%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -55.11%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH